Navigation Links
Refractory Hematological Malignances Treatment Opportunities Discussed in MP Advisors Report Published at MarketPublishers.com
Date:9/12/2013

London, UK (PRWEB) September 12, 2013

Recently, cancer treatment has witnessed considerable breakthroughs in terms of the development of innovative drug products. The success in clinical research in this therapeutic area and growth in investments are attributed to positive clinical data and regulatory approvals, expanding partnerships and mergers and acquisitions (M&A) activity.

Some companies that have already scored a success in the development of novel technology platforms and drugs to treat relapsed and refractory multiple myeloma (RRMM), are expected to follow a similar scenario to unfold in the treatment of recurrent/refractory MDS (RR-MDS, High-Risk MDS) and AML (relapsed/ refractory AML, R/R AML).

Insightful research report “Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics” worked out by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics
Published: August, 2013
Pages: 37
Price:    US$ 2,500.00
http://marketpublishers.com/report/company_reports/treating-refractory-hematological-malignancies-v-myelodysplastic-syndromes-mds-n-acute-myeloid-leukemia-aml-emerging-therapeutics.html

The report offers an insightful overview of the approved therapies for MDS and AML, discusses the unmet needs as well as limitations of the current standard of care (SOC) for relapsed and refractory patients. The study examines commercial opportunities in purchasing the therapy area, evaluates the competitive pressure in the sphere; makes up a comprehensive list of drugs (both early-stage and late-stage) in the clinic, and also uncovers data on their mechanism of action and companies developing them; besides profiling the leading companies. The report presents a review of the recent mergers and acquisitions in the area; covers products available for in-licensing; discusses the major trends and issues related to the therapeutic area.

Report Scope:

  •     Insightful overview of the disease and a detailed discussion of the unmet needs.
  •     Vital information on the drugs in pipeline including mechanism of action (MoA) and clinical stage of development.
  •     Review of the key milestones.
  •     Data on the launch timeline and commercial opportunity of late-stage pipeline (RR MDS and RR AML).
  •     Extensive overview of the mergers and acquisitions and licensing deals over the past five years.
  •     Evaluation of the in-licensing and/or mergers and acquisitions opportunity.
  •     Description of the competitive scenario and detailed profiles of companies, including their clinical drug data, milestones and valuation.

More insightful research reports by MP Advisors can be found at http://marketpublishers.com/members/mpadvisors/info.html.

About Us:

MarketPublishers.com is a multilingual hypermarket offering a rich collection of comprehensive studies on various markets, sectors, industries, companies, etc. We perform professional services aimed to equip our clients with high-quality research products and support critical decision-making.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11117498.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
2. Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at ReportsnReports.com
3. Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
4. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
5. Clinical insight improves treatment with new lung cancer drug
6. Rapid Asthma Treatment in ER May Prevent Admission
7. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. Mobile Stroke Units Might Trim Time to Treatment
11. Breast Cancer Treatment Side Effects May Last for Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology: